- Home
- SPKL vs MCRB Comparison
SPKL vs MCRB Comparison
Compare SPKL & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- MCRB
- Stock Information
- Founded
- SPKL 2021
- MCRB 2010
- Country
- SPKL United States
- MCRB United States
- Employees
- SPKL N/A
- MCRB N/A
- Industry
- SPKL
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- SPKL
- MCRB Health Care
- Exchange
- SPKL Nasdaq
- MCRB Nasdaq
- Market Cap
- SPKL 175.4M
- MCRB 141.9M
- IPO Year
- SPKL 2023
- MCRB 2015
- Fundamental
- Price
- SPKL $10.72
- MCRB $0.80
- Analyst Decision
- SPKL
- MCRB Buy
- Analyst Count
- SPKL 0
- MCRB 4
- Target Price
- SPKL N/A
- MCRB $5.63
- AVG Volume (30 Days)
- SPKL 10.4K
- MCRB 875.0K
- Earning Date
- SPKL 01-01-0001
- MCRB 03-04-2025
- Dividend Yield
- SPKL N/A
- MCRB N/A
- EPS Growth
- SPKL N/A
- MCRB N/A
- EPS
- SPKL 0.19
- MCRB N/A
- Revenue
- SPKL N/A
- MCRB $126,325,000.00
- Revenue This Year
- SPKL N/A
- MCRB N/A
- Revenue Next Year
- SPKL N/A
- MCRB N/A
- P/E Ratio
- SPKL $57.83
- MCRB N/A
- Revenue Growth
- SPKL N/A
- MCRB 12856.41
- 52 Week Low
- SPKL $10.23
- MCRB $0.54
- 52 Week High
- SPKL $11.95
- MCRB $1.53
- Technical
- Relative Strength Index (RSI)
- SPKL 62.29
- MCRB 46.38
- Support Level
- SPKL $10.69
- MCRB $0.81
- Resistance Level
- SPKL $10.73
- MCRB $0.84
- Average True Range (ATR)
- SPKL 0.02
- MCRB 0.04
- MACD
- SPKL -0.00
- MCRB 0.00
- Stochastic Oscillator
- SPKL 80.00
- MCRB 45.58
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.